Roche and Spark extend takeover yet again

Sept. 3, 2019

Roche and Spark Therapeutics announced yet another extension of the proposed $4.3 billion takeover, which has been pushed back more than three times.

Regulatory reviews will continue and the offer for Spark shares has a new deadline of October 1.

According to Roche, in this instance the offer was extended to give additional time for the U.S. Federal Trade Commission and the UK Competition and Markets Authority to complete their previously disclosed reviews of Roche’s pending acquisition of Spark.

Read the Reuters report.